Hormone and Drug-Mediated Modulation of Glucose Metabolism in a Microscale Model of the Human Liver

Tissue Engineering - Part C: Methods

Volumn 21, Issue 7, 2015, Pages 716-725

  Davidson, Matthew D ^a   Lehrer, Michael ^b   Khetani, Salman R ^a  

^a Department of Chemical and Biological Engineering and School of Biomedical Engineering   (United States)

^b Department of Ecosystem Science and Sustainability   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; DIGITAL STORAGE; DRUG PRODUCTS; ENDOCRINOLOGY; HORMONES; METABOLISM;

GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; LIVER METABOLISMS; MICRO SCALE MODELS; PHOSPHOENOLPYRUVATE CARBOXYKINASE; PRIMARY HUMAN HEPATOCYTES; PROOF OF CONCEPT; TYPE 2 DIABETES MELLITUS;

GLUCOSE;

GLUCAGON; GLUCOSE; GLYCOGEN; HORMONE; INSULIN; MESSENGER RNA; METFORMIN; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PHOSPHOENOLPYRUVATE CARBOXYKINASE 1; UNCLASSIFIED DRUG;

ARTICLE; COCULTURE; CONTROLLED STUDY; CRYOPRESERVATION; DIET RESTRICTION; FIBROBLAST; GENE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HORMONE RESPONSE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL; MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERNUTRITION; PCK1 GENE; PRIORITY JOURNAL; BIOLOGICAL MODEL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION PROFILING; LIVER; METABOLISM;

ANIMALIA;

COCULTURE TECHNIQUES; GENE EXPRESSION PROFILING; GLUCONEOGENESIS; GLUCOSE; HUMANS; LIVER; MODELS, BIOLOGICAL;

EID: 84934278403     PISSN: 19373384     EISSN: 19373392     Source Type: Journal    
DOI: 10.1089/ten.tec.2014.0512     Document Type: Article

References (45)

1. Haffner, S.M., D'Agostino, R., Mykkänen, L., Tracy, R., Howard, B., Rewers, M., Selby, J., Savage, P.J., and Saad, M.F. Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22, 562, 1999.
2. Hanley, A.J.G., Williams, K., Festa, A., Wagenknecht, L.E., D'Agostino, R.B., and Haffner, S.M. Liver markers and development of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study. Diabetes 54, 3140, 2005.
3. Sanyal, A.J., Campbell-Sargent, C., Mirshahi, F., Rizzo, W.B., Contos, M.J., Sterling, R.K., Luketic, V.A., Shiffman, M.L., and Clore, J.N. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183, 2001.
4. Cusi, K. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 16, 141, 2009.
5. Samuel, V.T., and Shulman, G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 148, 852, 2012.
6. Sherwin, R.S. Role of liver in glucose homeostasis. Diabetes Care 3, 261, 1980.
7. Viollet, B., and Foretz, M. Revisiting the mechanisms of metformin action in the liver. Ann Endocrinol (Paris) 74, 123, 2013.
8. Tahrani, A.A., Bailey, C.J., Del Prato, S., and Barnett, A.H. Management of type 2 diabetes: new and future developments in treatment. Lancet 378, 182, 2011.
9. Perry, R.J., Samuel, V.T., Petersen, K.F., and Shulman, G.I. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510, 84, 2014.
10. Tao, H., Zhang, Y., Zeng, X., Shulman, G.I., and Jin, S. Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice. Nat Med 20, 1263, 2014.
11. Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracklen, W., Dorato, M., Van Deun, K., Smith, P., Berger, B., and Heller, A. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32, 56, 2000.
12. Shih, H., Pickwell, G.V., Guenette, D.K., Bilir, B., and Quattrochi, L.C. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum Exp Toxicol 18, 95, 1999.
13. Raman, P., Donkin, S.S., and Spurlock, M.E. Regulation of hepatic glucose metabolism by leptin in pig and rat primary hepatocyte cultures. Am J Physiol Regul Integr Comp Physiol 286, R206, 2004.
14. Guillouzo, A., and Guguen-Guillouzo, C. Evolving concepts in liver tissue modeling and implications for in vitro toxicology. Expert Opin Drug Metab Toxicol 4, 1279, 2008.
15. LeCluyse, E.L., Witek, R.P., Andersen, M.E., and Powers, M.J. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit Rev Toxicol 42, 501, 2012.
16. Wilkening, S., Stahl, F., and Bader, A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos 31, 1035, 2003.
17. Hariparsad, N., Carr, B.A., Evers, R., and Chu, X. Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab Dispos 36, 1046, 2008.
18. Godoy, P., Hewitt, N.J., Albrecht, U., Andersen, M.E., Ansari, N., Bhattacharya, S., Bode, J.G., Bolleyn, J., Borner, C., Böttger, J., Braeuning, A., Budinsky, R.A., Burkhardt, B., Cameron, N.R., Camussi, G., Cho, C.-S., Choi, Y.-J., Craig Rowlands, J., Dahmen, U., Damm, G., Dirsch, O., Donato, M.T., Dong, J., Dooley, S., Drasdo, D., Eakins, R., Ferreira, K.S., Fonsato, V., Fraczek, J., Gebhardt, R., Gibson, A., Glanemann, M., Goldring, C.E.P., Gómez-Lechón, M.J., Groothuis, G.M.M., Gustavsson, L., Guyot, C., Hallifax, D., Hammad, S., Hayward, A., Häussinger, D., Hellerbrand, C., Hewitt, P., Hoehme, S., Holzhütter, H.-G., Houston, J.B., Hrach, J., Ito, K., Jaeschke, H., Keitel, V., Kelm, J.M., Kevin Park, B., Kordes, C., Kullak-Ublick, G.A., LeCluyse, E.L., Lu, P., Luebke-Wheeler, J., Lutz, A., Maltman, D.J., Matz-Soja, M., McMullen, P., Merfort, I., Messner, S., Meyer, C., Mwinyi, J., Naisbitt, D.J., Nussler, A.K., Olinga, P., Pampaloni, F., Pi, J., Pluta, L., Przyborski, S.A., Ramachandran, A., Rogiers, V., Rowe, C., Schelcher, C., Schmich, K., Schwarz, M., Singh, B., Stelzer, E.H.K., Stieger, B., Stöber, R., Sugiyama, Y., Tetta, C., Thasler, W.E., Vanhaecke, T., Vinken, M., Weiss, T.S., Widera, A., Woods, C.G., Xu, J.J., Yarborough, K.M., and Hengstler, J.G. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87, 1315, 2013.
19. Lu, Y., Zhang, G., Shen, C., Uygun, K., Yarmush, M.L., and Meng, Q. A novel 3D liver organoid system for elucidation of hepatic glucose metabolism. Biotechnol Bioeng 109, 595, 2012.
20. Bhatia, S.N., Balis, U.J., Yarmush, M.L., and Toner, M. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J 13, 1883, 1999.
21. Guguen-Guillouzo, C., Clément, B., Baffet, G., Beaumont, C., Morel-Chany, E., Glaise, D., and Guillouzo, A. Maintenance and reversibility of active albumin secretion by adult rat hepatocytes co-cultured with another liver epithelial cell type. Exp Cell Res 143, 47, 1983.
22. Khetani, S.R., and Bhatia, S.N. Microscale culture of human liver cells for drug development. Nat Biotechnol 26, 120, 2008.
23. Khetani, S.R., Kanchagar, C., Ukairo, O., Krzyzewski, S., Moore, A., Shi, J., Aoyama, S., Aleo, M., and Will, Y. Use of micropatterned co-cultures to detect compounds that cause drug induced liver injury in humans. Toxicol Sci 132, 107, 2012.
24. Rheinwald, J.G., and Green, H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 6, 331, 1975.
25. Schmittgen, T.D., and Livak, K.J. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3, 1101, 2008.
26. Robinson, B.H., and Oei, J. 3-Mercaptopicolinic acid, a preferential inhibitor of the cytosolic phosphoenolpyruvate carboxykinase. FEBS Lett 58, 12, 1975.
27. Collins, T.J. ImageJ for microscopy. BioTechniques 43 (1 Suppl), 25, 2007.
28. Diaz, G., Melis, M., Batetta, B., Angius, F., and Falchi, A.M. Hydrophobic characterization of intracellular lipids in situ by Nile Red red/yellow emission ratio. Micron 39, 819, 2008.
29. Smith, B.W., and Adams, L.A. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol 7, 456, 2011.
30. Koppe, S.W.P. Obesity and the liver: nonalcoholic fatty liver disease. Transl Res 164, 312, 2014.
31. Yamada, S., Otto, P.S., Kennedy, D.L., and Whayne, T.F. The effects of dexamethasone on metabolic activity of hepatocytes in primary monolayer culture. In Vitro 16, 559, 1980.
32. Wu, C., Okar, D.A., Kang, J., and Lange, A.J. Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes. Curr Drug Targets Immune Endocr Metabol Disord 5, 51, 2005.
33. Wang, D.-S., Jonker, J.W., Kato, Y., Kusuhara, H., Schinkel, A.H., and Sugiyama, Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 302, 510, 2002.
34. Xu, J.J., Henstock, P.V., Dunn, M.C., Smith, A.R., Chabot, J.R., and de Graaf, D. Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105, 97, 2008.
35. Ploss, A., Khetani, S.R., Jones, C.T., Syder, A.J., Trehan, K., Gaysinskaya, V.A., Mu, K., Ritola, K., Rice, C.M., and Bhatia, S.N. Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci U S A 107, 3141, 2010.
36. Postic, C., and Girard, J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118, 829, 2008.
37. Nagle, C.A., Klett, E.L., and Coleman, R.A. Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res 50 Suppl, S74, 2009.
38. Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., Ferrell, L.D., Liu, Y.-C., Torbenson, M.S., Unalp-Arida, A., Yeh, M., McCullough, A.J., and Sanyal, A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313, 2005.
39. Sohlenius-Sternbeck, A.-K. Determination of the hepatocellularity number for human, dog, rabbit, rat and mouse livers from protein concentration measurements. Toxicol In Vitro 20, 1582, 2006.
40. Rothman, D.L., Magnusson, I., Katz, L.D., Shulman, R.G., and Shulman, G.I. Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. Science 254, 573, 1991.
41. Kmieć, Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol 161, III, 2001.
42. Baffy, G. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 51, 212, 2009.
43. Huang, W., Metlakunta, A., Dedousis, N., Zhang, P., Sipula, I., Dube, J.J., Scott, D.K., and O'Doherty, R.M. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance. Diabetes 59, 347, 2010.
44. Ukairo, O., Kanchagar, C., Moore, A., Shi, J., Gaffney, J., Aoyama, S., Rose, K., Krzyzewski, S., McGeehan, J., Anderson, M.E., Khetani, S.R., and LeCluyse, E.L. Longterm stability of primary rat hepatocytes in micropatterned cocultures. J Biochem Mol Toxicol 27, 204, 2013.
45. Jungermann, K., and Kietzmann, T. Zonation of parenchymal and nonparenchymal metabolism in liver. Annu Rev Nutr 16, 179, 1996.